1[2]Mast EE, Alter MJ. Epidemiology of viral hepatitis: an overview.Semin Virol , 1993,4: 273-283.
2[3]Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus state ment on the management of chronic hepatitis B: An update for the Asian-Pacific consensus working parties on Hepatitis B. Gastroenterol Hepatol, 2003, 18: 239-245.
3[4]Lai CL, Chien RN, Leung NWY,et al. Aone-year trial of lamivudine for chronic hepatitis B. N Eng1 J Med, 1998,339:61-68.
4[8]The EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol, 2003, 38: 523-540.
5[9]Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology , 2001,34:1225-1241.
6[10]Li LL, Chun TW,Yin ML, et al. Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosup pression and chemotherapy. Hepatology , 2000,32:1183-1190.
7[11]Lok AS, McMahon BJ. Chronic hepatitis B. https://www, aasld. org/eweb.
8[12]Liaw YF, Sung JJY, Chow WC, et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial. Hepatology, 2003,38 (suppl 1 ): 262A.
9[13]De Jongh FE, Janssen HLA, De Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology , 1992,103:1630-1635.
10[14]Fontana RJ. Mangement of patients with decompensated HBV cirrhosis. Semin Liver Dis, 2003 ,23:89-100
